332 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The exploration of GLP-1 receptor agonists for weight loss in end-stage heart failure patients awaiting heart transplantation carries profound implications for clinical practice and patient access to life-saving proce…
Liraglutide's efficacy for glycemic control was compared against metformin monotherapy and metformin/glimepiride combination in 1091 Type 2 Diabetes patients.
Should this trial demonstrate that Insulin Degludec/Liraglutide (IDegLira) significantly improves Time in Range while simultaneously reducing markers of inflammation and endothelial dysfunction compared to a tradition…
Clinical trial NCT01451905 aims to characterize GLP-1 receptors in psoriatic skin and evaluate liraglutide for reducing psoriasis severity.
A completed observational study (NCT07374445) explored optimal liraglutide timing for patients remaining obese six months post-metabolic surgery.
For patients with severe insulin resistance in Type 2 Diabetes, optimizing glycemic control without excessive insulin burden is a critical challenge. High insulin doses often lead to weight gain and hypoglycemia, limi…
This trial directly confronts a significant challenge in GLP-1 therapy: mitigating the loss of lean muscle and bone mass during substantial weight reduction. If successful, the findings could establish a new, integrat…
This completed Phase II study for BI 456906 is a crucial step in developing new treatments for Type 2 Diabetes Mellitus and obesity. If positive, the findings could identify optimal dosing strategies for a novel compo…
If successful, this trial could establish semaglutide as a crucial adjunct therapy for individuals with Double Diabetes, potentially improving glycemic control beyond insulin alone and reducing overall insulin require…
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor …
Clarifying the link between semaglutide and NAION is critical for patient counseling and prescribing practices. If a significant association is confirmed, it could lead to updated guidelines for monitoring ocular heal…
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This study introduces a powerful SPRM methodology for characterizing peptide-receptor interactions directly on live cells, offering a significant advancement over traditional methods. This label-free, real-time approa…
Liraglutide significantly upregulated GLP1R expression and activated cAMP/PKA signaling, inducing apoptosis and cell cycle arrest in MCF7 breast and PC-3 prostate cancer cells.
Semaglutide offers a viable pathway for severely obese ESHF patients to become eligible for life-saving heart transplantation, potentially expanding access to this critical procedure. For clinicians, this suggests int…
This Phase 3 trial represents a crucial step in exploring Liraglutide as an adjunctive therapy for Type 1 Diabetes, a population with significant unmet needs beyond insulin. If the study's hypotheses were confirmed, i…
This foundational dataset provides an unprecedented tool for understanding diabetic microvascular disease at a systemic level, moving beyond organ-specific views. For researchers and clinicians, it offers a quantitati…
If GLP-1R agonists are found to significantly reduce Lipoprotein(a) (Lp(a)) levels, it would represent a substantial advancement in managing cardiovascular risk for Type 2 Diabetes patients. This finding would add a n…
Effective strategies for weight loss maintenance are crucial, as regain is a major challenge in obesity management. This trial's design, focusing on subjects who already achieved initial weight loss through diet, dire…
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
Understanding the intricate link between gut microbiota composition and semaglutide responsiveness could usher in a new era of personalized obesity treatment. If specific microbial profiles are found to predict who wi…
If this trial demonstrates that Semaglutide can effectively prevent or mitigate metabolic deterioration in patients on antipsychotics, it would represent a significant clinical breakthrough. Schizophrenia patients oft…
If successful, this trial could establish tirzepatide as a novel therapeutic option for Long COVID, addressing a critical gap in treatment. The remote, decentralized design of the study is particularly significant, de…
Comprehensive understanding of GLP-1RA reproductive safety is paramount for women of reproductive age managing obesity or type 2 diabetes. This review underscores the necessity for robust research to establish clear g…
This real-world study provides crucial validation that tirzepatide effectively promotes meaningful weight loss in both Type 2 Diabetes and non-diabetic obese adults, reinforcing its broad utility. The observed glycemi…
This discovery suggests HDM1005 could represent a significant advancement in treating metabolic disorders, potentially offering enhanced efficacy and a more convenient dosing schedule due to its extended half-life. Fo…
This Phase 2 study is crucial for understanding the potential of liraglutide (a GLP-1 receptor agonist) as a combination therapy for Type 2 Diabetes. The findings, once fully published, could highlight a more effectiv…
Optimizing treatment strategies for patients with Type 2 Diabetes and poor glycemic control is a critical unmet medical need, as uncontrolled blood sugar significantly increases the risk of severe complications. This …
This study is a methodological investigation designed to assess the concordance between real-world data analyses and the original SOUL Diabetes Trial results. As this record describes the study design and objectives r…
Understanding these pharmacokinetic interactions is critical for the safe and effective use of the semaglutide and NNC0480-0389 combination, especially for patients who may also be taking oral contraceptives or pain r…
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
This network meta-analysis provides a robust and comprehensive safety profile for oral Orforglipron, confirming its dose-dependent gastrointestinal side effects, which are common with GLP-1 RAs. The findings are cruci…
This case report highlights a critical, albeit rare, adverse event associated with rapid weight loss induced by GLP-1 receptor agonists in patients with cardiac implantable electronic devices (CIEDs). The finding sugg…
Understanding GLP-1's direct vascular effects could significantly expand its therapeutic potential beyond mere glucose control, offering new avenues for patient care. If GLP-1 or its analogues demonstrate independent …
Incretin-based therapies represent a highly promising and multifaceted approach in hypertension management, uniquely combining significant metabolic and cardiovascular benefits. Their ability to reduce blood pressure,…
This study addresses a crucial gap in managing obesity post-GLP-1 agonist therapy, which has significant implications for patient care and public health. If gradual withdrawal proves superior, it could establish a new…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This study highlights the critical importance of timing when discontinuing GLP-1RA/tirzepatide before pregnancy to mitigate gestational diabetes risk. While longer discontinuation periods appear safe, abrupt cessation…
This case report highlights a critical potential adverse effect of GLP-1 RAs on mood and behavior, particularly in vulnerable populations such as those with pre-existing Major Depressive Disorder. Given that GLP-1 rec…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated …
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated …
This study is significant because it addresses a critical unmet need for effective and manageable weight loss interventions in a highly complex and often overlooked patient population. The successful completion of the…